Blackstone focuses on large scale deals across technology infrastructure and healthcare technology

Nelson Advisors
9 minutes ago
15 min read

The Architecture of Modern Capitalism: Blackstone’s Strategic Hegemony in Technology Infrastructure and Healthcare Innovation

The global financial landscape has entered an era defined by the institutionalisation of private markets, where the traditional boundaries between equity, credit, and infrastructure have blurred in favour of massive, thematic capital deployment.

At the vanguard of this transformation is Blackstone, which, as of the conclusion of 2025, has solidified its position as the preeminent architect of the physical and technological foundations of the modern economy. By managing over $1.27 Trillion in assets, the firm has pivoted away from the broad-market indexing approach of the previous decade toward a concentrated focus on high-conviction mega-trends, most notably the build-out of artificial intelligence infrastructure and the technological revolution within the life sciences and healthcare sectors. The strategic rationale underpinning this shift is a recognition that the world is undergoing a multi-decade capital expenditure cycle, driven by the need for massive data processing capacity, stable and renewable energy sources, and more efficient, technology-enabled clinical development pathways.

The firm’s results for the fiscal year 2025 represent a definitive validation of this "scale-first" philosophy. Blackstone reported its highest annual inflows in years, reaching $239.4 Billion, while deploying a record $138.2 billion into sectors that exhibit structural tailwinds insulated from broader macroeconomic volatility. This aggressive deployment is not merely a function of capital availability but is guided by a "picks and shovels" investment thesis, where the firm seeks to own the critical, non-discretionary infrastructure that powers the digital and biological revolutions.

Whether through the acquisition of the world’s largest data centre platforms or the financing of late-stage therapies for global chronic diseases, the firm’s activities in 2024 and 2025 underscore a broader institutional shift toward private capital as the primary solver of complex, large-scale industrial and societal challenges.

The Financial Engine: Capital Dynamics and the Perpetual Pivot

The ability to execute multi-billion dollar deals in highly technical sectors requires a financial structure that transcends the limitations of traditional, closed-ended private equity funds. Blackstone has systematically re-engineered its balance sheet and fund structures to emphasize perpetual capital, which now accounts for a significant portion of its total assets under management. This transition allows the firm to take a "generational" view of its assets, particularly in infrastructure and real estate, where the timeline for value creation and capital recycling often extends beyond the typical ten-year fund life.

Analysis of Assets Under Management and Inflow Velocity

By the end of the fourth quarter of 2025, Blackstone’s total assets under management (AUM) reached a record $1,274.9 billion, a 13% increase from the $1,127.2 billion reported at the close of 2024. This growth was catalyzed by an unprecedented acceleration in fundraising, particularly within the private wealth and institutional infrastructure channels. In 2025, the firm saw $239.4 billion in total inflows, driven by the demand for strategies that offer yield, inflation protection, and exposure to high-growth technology themes.

Financial Metric	FY 2024 (Actual)	FY 2025 (Actual)	Year-over-Year Change
Total Assets Under Management (AUM)	$1,127.2 Billion	$1,274.9 Billion	+13.1%
Fee-Earning AUM	$830.7 Billion	$921.7 Billion	+11.0%
Perpetual Capital AUM	$444.8 Billion	$523.6 Billion	+17.7%
Total Annual Inflows	$171.5 Billion	$239.4 Billion	+39.6%
Total Annual Deployment	$133.9 Billion	$138.2 Billion	+3.2%
Total Annual Realizations	$87.1 Billion	$125.6 Billion	+44.2%

The shift toward perpetual capital is a critical competitive moat for Blackstone. At $523.6 billion, perpetual capital now represents approximately 41% of the firm's total AUM, providing a highly stable and predictable stream of management fees that are less sensitive to the cyclicality of the exit environment. This stability has enabled the firm to maintain its investment pace even during periods of market volatility, as seen in the $138.2 billion deployed in 2025. The velocity of realisations also saw a marked improvement in 2025, with $125.6 billion in assets liquidated, reflecting a robust recovery in the deal environment and the firm’s ability to find strategic buyers for its high-quality infrastructure and technology holdings.

Segment Performance and Earnings Quality

Blackstone's earnings profile in 2025 was characterized by the strength of its core segments, particularly Infrastructure and Private Equity, which benefited from significant appreciation in technology-linked assets. Distributable Earnings (DE), a key metric for shareholder returns, rose to $7.1 billion for the full year, while Fee Related Earnings (FRE) reached $5.7 billion. This growth was supported by mid-teens growth in base management fees across three of the four primary business segments in the final quarter of 2025.

Earnings Measure ($ in millions)	FY 2024	FY 2025	Change (%)
Management and Advisory Fees, Net	$7,188.9	$8,075.6	+12.3%
Fee Related Earnings (FRE)	$5,321.7	$5,655.9	+6.3%
Distributable Earnings (DE)	$5,966.7	$7,110.9	+19.2%
Net Accrued Performance Revenues	$6,303.0	$6,743.3	+7.0%

The appreciation across strategies led to higher Net Accrued Performance Revenues of $6.7 billion by the end of 2025. A significant driver of this appreciation was the infrastructure portfolio, where Blackstone Infrastructure Partners (BIP) generated an 18% net return annually since inception seven years ago. In 2025, the infrastructure segment produced a gross return of 23.5%, primarily driven by the massive value creation within its data center platform, QTS. This performance highlights the firm's ability to identify "new-economy" assets that command premium valuations due to their critical role in the digital supply chain.

Technology Infrastructure: Scaling the Physical Foundation of AI

The most significant strategic undertaking in Blackstone’s history is its current effort to build the physical infrastructure required to support the global artificial intelligence revolution. The firm identifies AI as the single most consequential force shaping the global economy, characterising it as a generational investment opportunity that requires trillions of dollars in capital for data centers, power grids, and connectivity. Blackstone’s approach is defined by its massive scale, allowing it to move beyond individual property deals to develop entire ecosystems of digital and energy infrastructure.

The Global Data Center Portfolio: QTS and AirTrunk

Blackstone has established itself as the world’s largest provider of data centres, with a global portfolio valued at approximately $110 Billion as of early 2026. This dominance was achieved through a series of landmark acquisitions and a massive development program designed to meet the explosive demand from hyperscalers like Amazon, Google and Microsoft, who are projected to spend over $2 Trillion on data infrastructure over the next five to seven years.

The cornerstone of this strategy was the 2021 acquisition of QTS (Quality Technology Services) for $10 Billion. Since the acquisition, QTS has seen its leased portfolio grow more than ninefold, becoming the fastest-growing data center company in the world. In 2025 alone, QTS grew its leasing activity by 50%, reflecting the relentless demand for AI-ready capacity. The value proposition of QTS lies in its significant land bank, which is capable of supporting an additional $100 Billion of future development, much of it 100% pre-leased with long-term contracts.

Strategic Data Center Asset	Region	Transaction Value	Performance/Impact
QTS	Global/U.S.	$10 Billion (2021)	Leased portfolio grew >9x under Blackstone ownership.
AirTrunk	APAC	$16 Billion (2024)	Largest APAC operator; solidifies global leadership.
Firmus	Australia	$10 Billion (2026)	Private credit facility for high-density "AI Factories."

In 2024, Blackstone further expanded its dominance with the $16 Billion acquisition of AirTrunk, the largest data center operator in the Asia-Pacific region. This transaction allowed Blackstone to provide a global, standardized solution to its hyperscale customers, who require consistent infrastructure across the Americas, Europe, and Asia. By early 2026, the firm extended its reach into specialized AI infrastructure with a $10 billion private credit facility for Firmus, an Australian startup building high-density "AI Factories" supported by Nvidia technologies. These facilities are designed with advanced liquid cooling and energy integration to handle the intense thermal and power requirements of large language model training.

The Energy Nexus: Power as the Ultimate Constraint

A primary second-order insight driving Blackstone’s strategy is that the growth of AI is increasingly constrained not by silicon or space, but by the availability of reliable, high-voltage power. U.S. electricity demand is projected to grow by 40% over the next decade, a stark shift after twenty years of stagnant demand. This surge is driven by a trifecta of forces: the AI build-out, the electrification of the automotive and heating sectors, and the "re-industrialisation" of domestic manufacturing.

Blackstone has positioned itself as a "solution provider" to this energy crisis by integrating power generation and transmission into its infrastructure platform. The firm views the supply-demand imbalance in power as one of its highest-conviction investment themes, requiring an estimated $2.4 Trillion of capital in the broader utility and power sectors. In July 2025, the firm announced an unprecedented initiative in Pennsylvania, committing to invest over $25 billion into the state's digital and energy infrastructure. This plan includes a joint venture with PPL Corporation to develop new natural gas power generation facilities, providing the firm with the ability to co-locate data centers with stable, on-site energy production.

Energy Infrastructure Focus	Role in Ecosystem	Strategic Mechanism
Invenergy	Renewables Leader	Largest independent developer in North America; grid-scale solar/wind.
Bridge Power (PPL JV)	Base-load Stability	Natural gas generation to ensure consistent power for AI clusters.
Grid & Transmission	Modernization	Addressing the 40+ year average age of the U.S. grid.
Battery & Storage	Resilience	Investing in the backup systems that ensure 99.999% uptime.

The firm's energy strategy is pragmatic rather than ideological. While it is the largest owner of renewables through Invenergy, it also invests heavily in midstream natural gas assets and "bridge power" solutions to ensure that data centres have the 24/7 reliability they require. This integrated approach allows Blackstone to capture value across the entire AI value chain, from the power plants and transmission lines to the data centres and the fiber networks that connect them.

Digital Connectivity and the "Last Mile" of Data

The third pillar of Blackstone's technology infrastructure strategy is digital connectivity, which encompasses the wireless networks and fiber-optic systems that transmit the data processed in its centers. The firm recognises that as the world moves toward 5G and AI enabled edge computing, the demand for robust, secure, and fast digital connectivity will grow exponentially.

Blackstone Infrastructure Partners holds a 35% stake in Phoenix Tower International (PTI), a leading private cell tower platform with over 14,000 sites across the Americas and Europe. Cell towers are viewed as a "mission-critical" infrastructure asset class with long-term growth tailwinds and highly durable cash flows. Additionally, the firm has invested in Hotwire, a provider of fiber-to-the-home services, and other digital infrastructure platforms that enable mobile connectivity and cloud-based computing. These investments ensure that Blackstone is not only a landlord for data but also a facilitator of its global movement.

Healthcare Technology: Transforming Medicine through Scale and Software

Parallel to its infrastructure dominance, Blackstone has re-engineered its healthcare strategy to focus on the high-margin, technology-enabled sectors of life sciences and healthcare IT. The firm has moved away from traditional, labour intensive healthcare services toward a model that leverages clinical expertise, data science and massive capital to bridge the "innovation gap" in global medicine.

Blackstone Life Sciences (BXLS): Institutionalising Drug Development

Blackstone Life Sciences (BXLS) is the world's largest private life sciences investment platform, with $12 Billion in assets under management and a team composed of medical doctors and PhDs. The strategic mission of BXLS is to fill a funding void in the pharmaceutical industry, where promising late-stage clinical assets are often deprioritised due to corporate budget constraints rather than a lack of scientific merit.

The BXLS model is defined by its ability to de-risk assets and achieve a Phase III success rate of nearly 90%, compared to the industry average of 60% (or 48% depending on the specific sub-sector metrics). This outperformance is achieved through a combination of collaboration, ownership, and non-dilutive financing.

Case Study: The Anthos Therapeutics Lifecycle

The acquisition and sale of Anthos Therapeutics serves as the definitive case study for the BXLS "ownership" strategy. Anthos was founded in 2019 as a joint venture between Blackstone and Novartis to develop abelacimab, a novel anticoagulation therapy for the treatment of cardiometabolic diseases. Blackstone provided the majority of the funding and operational leadership to advance the drug through advanced clinical trials.

In April 2025, Novartis completed the reacquisition of Anthos in a deal valued at up to $3.1 billion, including a $925 million upfront payment. The transaction validated Blackstone’s ability to identify a high-potential but deprioritised asset, assemble a world-class team to de-risk it, and return it to a strategic partner at a substantial premium once its clinical viability was established.

High-Conviction Partnerships: Alnylam and Moderna

BXLS also engages in massive, non-dilutive collaborations with industry leaders. In 2020, the firm entered into a $2 Billion strategic collaboration with Alnylam, the largest private financing of a pre-profitability biotech company. This included the acquisition of a royalty interest in Leqvio, a genomics-based cholesterol medicine that reduces LDL by more than 50%. This structure provided Alnylam with significant capital to fund its pipeline without diluting existing shareholders, while Blackstone secured a long-term, uncorrelated return stream based on product sales.

In March 2024, BXLS announced a $750 Million collaboration with Moderna to fund the late-stage development of its influenza mRNA vaccine program. This partnership highlights Blackstone's role as a "capital partner of choice" for the most innovative companies in the world, providing the scale necessary to accelerate life-saving technologies to market.

BXLS Strategic Investment	Target Area	Transaction Value	Outcome/Objective
Anthos Therapeutics	Anticoagulation	$3.1 Billion (Exit)	Reacquired by Novartis; clinical success validated.
Alnylam	Cardiovascular	$2.0 Billion	50% royalty interest in Leqvio sales.
Moderna	mRNA Vaccines	$750 Million	Funding late-stage influenza vaccine development.
Autolus	T-Cell Therapy	$250 Million	Clinical development of obe-cel for ALL.
Medtronic	Diabetes	$337 Million	Development of next-gen diabetes devices.

Clinical Research Infrastructure: Modernising the CRO

Beyond drug development, Blackstone has recognised that the efficiency of the entire life sciences industry depends on a modern, technology enabled clinical trial ecosystem. To capture this trend, the firm has made major investments in Contract Research Organisations (CROs) and clinical technology platforms that use AI and data science to accelerate study startup and improve participant safety.

In August 2022, Blackstone and CPPIB completed the acquisition of a majority stake in Advarra, a leading provider of regulatory, quality, and compliance solutions for clinical trials, at a valuation of approximately $5 Billion. Advarra’s software connects sponsors, CROs, and researchers, providing a unified platform to manage the increasingly complex data requirements of modern trials. This investment reflects Blackstone's commitment to the "operating system" of life sciences research.

Further expanding its global reach, Blackstone formed a strategic alliance with CMIC Holdings in May 2025, taking a 60% stake in its CRO business. CMIC is a dominant player in the Japanese market, and the partnership aims to leverage Blackstone’s global network to transform CMIC into a leading CRO across the Asia-Pacific region. By owning the infrastructure of clinical research, Blackstone gains proprietary insights into global drug development trends, which in turn informs its capital allocation in the BXLS fund.

Healthcare IT: The Evolution of Payor Systems

The third pillar of Blackstone's healthcare strategy is the modernisation of the administrative and financial systems that power the U.S. healthcare economy. The firm has focused on "Core Administrative Processing Systems" (CAPS) and AI-driven platforms that help insurers manage the rising complexity of claims and member care.

The acquisition and subsequent evolution of HealthEdge Software represents a landmark success in this segment. Blackstone Growth acquired HealthEdge in 2020 for approximately $700 Million. Under Blackstone’s ownership, HealthEdge integrated multiple strategically important software solutions, including The Burgess Group (payment integrity), Altruista Health (care management), and Wellframe (digital member engagement). This buy-and-build strategy transformed HealthEdge into a comprehensive, cloud-native technology platform for healthcare payors.

In April 2025, Blackstone sold its stake in HealthEdge to Bain Capital. While official terms were not disclosed, reports indicated the business was valued at approximately $3 billion, a fourfold increase in value over five years. This exit demonstrates Blackstone’s ability to modernize a legacy sector through aggressive technology investment and operational excellence.

Healthcare Technology Platform	Core Function	Strategic Context
Advarra	Regulatory/Compliance	$5B valuation; connecting sponsors and sites via software.
HealthEdge	Payor IT (CAPS)	Transformed into an AI-native "operating system" for insurers.
Hydrogen Health	Virtual Primary Care	AI-powered triage and diagnosis JV with Elevance Health.
Chartis	Advisory/Transformation	Advisor to providers/payors on digital and clinical shifts.

The Interconnected Portfolio: Synergies of Data, Energy and Biology

The convergence of technology infrastructure and healthcare technology within the Blackstone portfolio creates a powerful "flywheel" effect, where proprietary insights in one sector inform capital deployment in another. The firm’s massive scale allows it to see early trends across its 270+ portfolio companies and 13,000 real estate assets, providing a "vantage point" that few other investors possess.

AI as the Catalyst for Life Sciences Innovation

One of the most profound insights emerging from the Blackstone portfolio is the role of AI in accelerating life sciences discovery. As scientists begin to use AI and machine learning together with genetics and genomics, they are discovering the genes that cause diseases at an unprecedented pace. Blackstone’s ownership of data centers (which provide the compute power) and its investments in BXLS (which fund the resulting therapies) position the firm at the intersection of this biological-technological convergence.

This synergy is also evident in the clinical trial space. As CROs like Advarra and CMIC adopt AI to optimise recruitment and data analysis, the cost and time required to bring a drug to market decrease, increasing the potential returns for the BXLS fund. The firm is effectively building the "computational and physical stack" for the future of medicine.

Operational Alpha: The Role of Data Science

Blackstone’s ability to drive value in its large-scale deals is increasingly dependent on its internal Data Science and Digital Excellence teams. These teams work across the portfolio to modernize operations through AI, process optimization, and technology upgrades. For example, the Data Science team analyses real-time spending data to identify shifts in consumer behavior, which informs the firm's outlook on its logistics and consumer-sector investments.

In the healthcare segment, technology is no longer a back-office function but a strategic lever for accelerating EBITDA and scaling platforms. By proactively investing in the remediation of "tech debt" and modernizing infrastructure, Blackstone enables its portfolio companies to achieve synergies and growth that they would struggle to achieve independently. This systematic transformation is a key driver of the 35% EBITDA margins seen in the firm’s U.S. private equity portfolio by late 2025.

Sustainability and the Energy Transition

Blackstone’s massive investment in energy infrastructure is closely tied to its ESG (Environmental, Social, and Governance) strategy. The firm recognises that the scale of investment required to reach net-zero emissions by 2050, estimated at $4.5 Trillion annually, cannot be met by public funding alone. Through its Energy Transition funds, Blackstone is positioning itself as a key financier of the global decarbonization effort.

This is particularly relevant for the data center sector, which is a major consumer of electricity. Blackstone’s commitment to help its clients reach net-zero emissions involves replacing outdated infrastructure with high-efficiency solutions and investing in renewable energy projects that Achieve at least a 30% reduction in greenhouse gas emissions. By aligning its infrastructure builds with sustainability goals, Blackstone reduces regulatory risk and enhances the long-term terminal value of its assets.

ESG Focus Area	Strategic Objective	Measure of Success
Decarbonization	Net-zero by 2050	$300M fund for upgrades reducing GHG by >30%.
Energy Transition	Profitable pathways to green	Expansion of Blackstone Energy Transition Partners V.
Governance	Sustainability reporting	Robust ISSB and GRI alignment to ensure transparency.
Workforce	STEM representation	Increasing women in STEM roles across the portfolio.

Strategic Conclusions and the 2026 Macroeconomic Horizon

As Blackstone enters 2026, it does so with a portfolio that is uniquely positioned to benefit from the prevailing mega-trends of the decade. The firm's leadership expects fundraising in 2026 to exceed even the record levels of 2025, driven by the ongoing shift of institutional capital into private markets and the resilient performance of its thematic strategies.

The Deal Dam is Breaking

Following a period of relatively slow deal activity in 2023 and early 2024, Blackstone anticipates a significant rebound in transaction volume in 2026. This "dam-breaking" effect is driven by cooling inflation, which is giving central banks room to lower interest rates, thereby reducing financing costs and encouraging realizations. The firm's realisations reached $125.6 Billion in 2025, and this momentum is expected to continue as private equity enters 2026 with strong momentum and expanding opportunity sets.

Risks and Vulnerabilities

Despite the positive outlook, Blackstone’s scale-driven strategy is not without risks. The primary challenge remains the potential for rising electricity prices and grid instability, which could slow the deployment of AI infrastructure. Furthermore, while the firm has successfully pivoted to perpetual capital, the sheer size of its platform means that any single transaction, even a multi-billion dollar one, has a diminishing marginal impact on the overall firm performance.Investors must also remain vigilant regarding the firm’s high levels of debt and the coverage of its dividend payouts in a fluctuating interest rate environment.

The Enduring Power of Scale

The ultimate takeaway from Blackstone’s activities in 2024 and 2025 is that scale has become the definitive competitive moat in alternative asset management. The ability to deploy $138 Billion in a single year, to acquire $16 billion data centre platforms and to finance $2 Billion drug development collaborations allows Blackstone to capture value that is fundamentally inaccessible to smaller competitors. By owning the "physical layer" of the digital world and the "biological layer" of human health, Blackstone has transformed itself from a traditional investment firm into a permanent institution of global infrastructure and innovation.

As the AI build-out enters its most capital intensive phase and the life sciences industry reaches a technological inflection point, Blackstone’s role as the primary provider of scale capital and operational expertise will only grow more central to the global economic narrative. The firm is no longer just betting on the future; it is building it, one data center and one clinical trial at a time..

Nelson Advisors > European MedTech and HealthTech Investment Banking

Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk

Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital

Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb

Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk

#NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech